Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Jul 2018. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 468563019 | Betamethasone+salicylic acid 0.05/3% ointment | en | Synonym | Inactive | Entire term case insensitive | SNOMED CT core module |
| 721426011 | Betamethasone+salicylic acid 0.05/3% ointment (substance) | en | Fully specified name | Inactive | Only initial character case insensitive | SNOMED CT core module |
| 1192588019 | Betamethasone+salicylic acid 0.05/3% ointment (product) | en | Fully specified name | Inactive | Entire term case insensitive | SNOMED CT core module |
| 3692869013 | Betamethasone (as betamethasone dipropionate) 500 microgram/g and salicylic acid 30 mg/g cutaneous ointment | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| 3692870014 | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | en | Synonym | Inactive | Entire term case insensitive | SNOMED CT core module |
| 3692871013 | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 46767201000001110 | Salicylic acid 3% / Betamethasone dipropionate 0.05% ointment | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom Edition module |
| 60129501000001119 | Betamethasone dipropionate 0.05% / Salicylic acid 3% ointment | en | Synonym | Active | Only initial character case insensitive | SNOMED CT United Kingdom Edition module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Is a | Product containing betamethasone and salicylic acid | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Betamethasone | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Adrenal hormone | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Corticosterone | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Adrenal hormone agent | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Salicylic acid | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Keratolytic agent | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Glucocorticoid hormone | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Topical agent | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Cutaneous AND/OR transdermal dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Is a | Product containing betamethasone in topical dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Is a | Product containing salicylic acid in topical dosage form | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Conventional release cutaneous ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength denominator value | 1 | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength denominator unit | gram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has basis of strength substance | Betamethasone | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength numerator value | 30 | false | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength numerator value | 500 | false | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has basis of strength substance | Salicylic acid | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has precise active ingredient | Salicylic acid | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has concentration strength numerator unit | microgram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has precise active ingredient | Betamethasone dipropionate | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Is a | Product containing only betamethasone and salicylic acid in cutaneous dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Plays role | Antifungal therapeutic role | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Cutaneous dose form | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Is a | Salicylic acid + Betamethasone | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Conventional release cutaneous ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has NHS dm+d (dictionary of medicines and devices) dose form indicator | Continuous dose form indicator | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has NHS dm+d (dictionary of medicines and devices) controlled drug category | Controlled drug category No Controlled Drug Status | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has NHS dm+d (dictionary of medicines and devices) VMP (Virtual Medicinal Product) route of administration | Topical route | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has NHS dm+d (dictionary of medicines and devices) VMP (Virtual Medicinal Product) ontology form and route | ointment.cutaneous ontology form and route | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Betamethasone | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has NHS dm+d (dictionary of medicines and devices) VMP (Virtual Medicinal Product) route of administration | Cutaneous | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Salicylic acid | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has active ingredient | Betamethasone dipropionate | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Conventional release cutaneous ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Conventional release cutaneous ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Count of base of active ingredient | 2 | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | VMP prescribing status (attribute) | VMP valid as a prescribable product | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | VMP non-availability indicator | Available | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has manufactured dose form | Ointment | false | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has NHS dm+d (dictionary of medicines and devices) basis of strength substance | Betamethasone | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has specific active ingredient | Salicylic acid | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has specific active ingredient | Betamethasone dipropionate | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has dispensed dose form | Ointment | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Is a | Virtual medicinal product | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Has basis of strength substance | Betamethasone | false | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Betamethasone+salicylic acid 0.05/3% ointment - product | Is a | False | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic 0.05%/3% ointment (Organon Pharma (UK) Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (PI) (Waymade Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (PI) (Dowelhurst Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Salicylic acid 3% / Betamethasone dipropionate 0.05% ointment 100 gram | Is pack of | False | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Salicylic acid 3% / Betamethasone dipropionate 0.05% ointment 30 gram | Is pack of | False | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (Doncaster Pharmaceuticals Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (Sigma Pharmaceuticals Plc) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Salicylic acid 3% / Betamethasone dipropionate 0.05% ointment 30 gram | Has VMP | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Salicylic acid 3% / Betamethasone dipropionate 0.05% ointment 100 gram | Has VMP | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (Lexon (UK) Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (Mawdsley-Brooks & Company Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier | |
| Diprosalic ointment (Necessity Supplies Ltd) | Is a | True | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 gram and salicylic acid 30 milligram/1 gram conventional release cutaneous ointment | Inferred relationship | Existential restriction modifier |
This concept is not in any reference sets